



FOR IMMEDIATE RELEASE

CORE LAB ANNOUNCES THE RESULTS OF ITS 2019 ANNUAL SHAREHOLDER MEETING

AMSTERDAM (24 May 2019) – Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") announces it held its annual shareholder meeting on May 23, 2019 in Amsterdam, The Netherlands. At that meeting, the shareholders re-elected Ms. Martha Z. Carnes and Mr. Michael Straughen and elected Mr. Gregory B. Barnett to the supervisory board. The vote results for all matters voted upon at the annual meeting of shareholders on May 23, 2019 are as follows:

Proposal No. 1 - Election of Class II Directors: The election of each Class II supervisory director was approved as follows:

<u>Nominee</u>	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
Martha Z. Carnes	34,776,105	268,259	3,040,397
Michael Straughen	34,499,830	544,534	3,040,397
Gregory B. Barnett	34,780,230	264,134	3,040,397

Proposal No. 2 – Appointment of KPMG: The appointment of KPMG as the Company's independent registered public accountants for the fiscal year ending December 31, 2019 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,826,576	180,519	77,666	0

Proposal No. 3 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2018 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,933,422	29,802	121,537	0

Proposal No. 4 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on May 23, 2019 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,870,724	73,097	140,940	0

Proposal No. 5 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until November 23, 2020 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,720,482	202,115	162,164	0

Proposal No. 6 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until November 23, 2020 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
34,922,157	99,489	22,718	3,040,397

Proposal No. 7 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 23, 2020 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
31,578,419	3,435,898	30,047	3,040,397

Proposal No. 8 - Approve the Compensation of the Company's Executive Officers: The compensation program regarding the Company's named executive officers was approved, on an advisory basis, as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
32,687,322	2,199,007	158,035	3,040,397

For more information contact:

Gwen Y. Schreffler - SVP Corporate Development and Investor Relations, +1 713 328 6210
investor.relations@corelab.com

###